Skip to main content
. Author manuscript; available in PMC: 2022 Jul 1.
Published in final edited form as: Diabetologia. 2021 Mar 26;64(7):1674–1689. doi: 10.1007/s00125-021-05431-5

Fig. 2.

Fig. 2

FMC activates the SIRT1/LXR signalling pathway in BRECs and neuronal (R28) cells. FMC (0% FBS, 24 h) in BRECs activates (a) SIRT1 HDAC activity, with TNF-α used as a positive control, (b) Sirt1 mRNA expression, and (c) increased expression of RCT genes (Abca1 and Abcg1). (d) Vcam1 is decreased after treatment with FMC conditions. (e) Treatment of R28 cells with FMC increases expression of Sirt1 and Lxrα mRNA, as well as LXRα activity, as measured by Abca1 mRNA expression *p<0.05, **p<0.01, ***p<0.001. Data are represented as mean ± SEM. Ctl, control